Novo Nordisk® w patient initiations in the US in e signs of gradual recovery NBRx development US Saxenda® indexed NBRx development , lockdown nted in most states GLP-1 Index 140 13 March, lockdown implemented in most states Saxenda® 120 100 81 80 86 60 20 5/1/20 6/1/20 7/J1u/2l 0 2020 40 1/F2/e2b0 2/2/20 3/2/20 2020 4/2/20 5/2/20 6/2/20 7/2J/u2l0 2020
Download PDF file